Biding antibodies in half and full dose BNT162b2 vaccinated people under 55 years of age

Comparison of humoral response in half and full dose of BNT162b2 vaccinated in people under 55 years of age

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210708051820N1

Enrollment

Registered

2021-08-06

Start date

2021-01-27

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The humoral response to the half-dose of BNT162b2-vaccine.. Other serum reaction due to vaccination

Interventions

Intervention 1: Intervention group: Vaccination with BNT162b2 vaccine (Comirnaty, Pfizer/BioNTech), 2 doses at 15ug each, dose interval 21 days. Blood draws for antibody testing: day 1, 8, 21, 28-30 (

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Willingness to take part in the clinical trial Age between 18 and 55 years old

Exclusion criteria

Exclusion criteria: Age above 55 years old Diagnosed with diabetes, hypertension, heart disease, chronic pulmonary diseases, severe allergies Obesity as defined by BMI > 30

Design outcomes

Primary

Measure	Time frame
Anti-SARS-CoV-2 antibody level. Timepoint: On the day of dose-2 of the vaccine and 8-10 days later. Method of measurement: IVD Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics).	—

Countries

Poland

Contacts

Public ContactKrzysztof Lukaszuk

Invicta Research and Development Center

sekretariatlukaszuk@invicta.pl+48 58 585 88 10

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026